• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Ph/BCR-ABL阴性骨髓增殖性肿瘤患者的症状负担评估]

[The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].

作者信息

Xu Junqing, Xu Zefeng, Wang Jingya, Li Bing, Sun Xiujuan, Qin Tiejun, Zhang Yue, Zhang Hongli, Fang Liwei, Pan Lijuan, Hu Naibo, Qu Shiqiang, Xiao Zhijian

机构信息

Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC. The State Key Laboratory of Experimental Hematology, Tianjin 300020, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):26-9. doi: 10.3760/cma.j.issn.0253-2727.2016.01.005.

DOI:10.3760/cma.j.issn.0253-2727.2016.01.005
PMID:26876249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342297/
Abstract

OBJECTIVE

To investigate the value of myeloproliferative neoplasms Symptom Assessment Form total symptom score (MPN-SAF-TSS)in assessing constitutional symptoms among Ph/BCR- ABL negative myeloproliferative neoplasm (MPN)patients.

METHODS

A cohort of 628 MPN patients were evaluated by MPN- SAF- TSS.

RESULTS

Fatigue was the most common symptom (76.0%, 76.2%vs 89.9%)and the highest average severity of all the symptoms (3.46±2.97, 3.47±2.99vs 4.74±3.04 scores)among polycythemia vera (PV), essential thrombocythemia (ET)and primary myelofibrosis (PMF)patients. Using the MPN- SAF- TSS analysis, PMF patients showed highest burden of symptoms (28.9 ± 19.1), followed by PV patients (19.2 ± 16.8), and finally ET patients (17.1 ± 15.3). Instinct differences were observed between PMF and PV patients (χ(2)=6.371,P=0.021), PMF and ET patients (χ(2)= 14.020,P<0.001). No significant difference was found between PV and ET patients (χ(2)=2.281,P=0.191).

CONCLUSION

MPN- SAF- TSS was effective in evaluating the symptomatic burden among Ph/BCRABL negative MPN patients and could be used for serial assessment in this clinical setting.

摘要

目的

探讨骨髓增殖性肿瘤症状评估表总症状评分(MPN-SAF-TSS)在评估Ph/BCR-ABL阴性骨髓增殖性肿瘤(MPN)患者全身症状中的价值。

方法

采用MPN-SAF-TSS对628例MPN患者进行评估。

结果

在真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)患者中,疲劳是最常见的症状(分别为76.0%、76.2%和89.9%),且是所有症状中平均严重程度最高的(评分分别为3.46±2.97、3.47±2.99和4.74±3.04)。通过MPN-SAF-TSS分析,PMF患者的症状负担最高(28.9±19.1),其次是PV患者(19.2±16.8),最后是ET患者(17.1±15.3)。PMF与PV患者之间(χ(2)=6.371,P=0.021)、PMF与ET患者之间(χ(2)= 14.020,P<0.001)存在显著差异。PV与ET患者之间无显著差异(χ(2)=2.281,P=0.191)。

结论

MPN-SAF-TSS可有效评估Ph/BCR-ABL阴性MPN患者的症状负担,并可用于该临床环境中的系列评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e224/7342297/fb2295bd34b6/cjh-37-01-026-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e224/7342297/fb2295bd34b6/cjh-37-01-026-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e224/7342297/fb2295bd34b6/cjh-37-01-026-g001.jpg

相似文献

1
[The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].[Ph/BCR-ABL阴性骨髓增殖性肿瘤患者的症状负担评估]
Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):26-9. doi: 10.3760/cma.j.issn.0253-2727.2016.01.005.
2
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.费城染色体阴性骨髓增殖性肿瘤的临床表现及并发症危险因素
Asian Pac J Cancer Prev. 2015;16(12):5013-8. doi: 10.7314/apjcp.2015.16.12.5013.
3
Myeloproliferative neoplasia: a review of clinical criteria and treatment.骨髓增殖性肿瘤:临床标准与治疗综述
Neth J Med. 2012 May;70(4):159-67.
4
Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.髓系增殖性肿瘤中水源性瘙痒和非水源性瘙痒的差异:一项 500 例患者的观察性研究。
J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1175-1183. doi: 10.1111/jdv.18990. Epub 2023 Mar 9.
5
Assessing disease burden in patients with classic MPNs.评估经典骨髓增殖性肿瘤患者的疾病负担。
Best Pract Res Clin Haematol. 2014 Jun;27(2):107-19. doi: 10.1016/j.beha.2014.07.006. Epub 2014 Jul 18.
6
Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.巴西患者中TNF基因多态性与JAK2(V617F)骨髓增殖性肿瘤的关联。
Blood Cells Mol Dis. 2016 Mar;57:54-7. doi: 10.1016/j.bcmd.2015.12.005. Epub 2015 Dec 10.
7
Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis.骨髓增殖性肿瘤症状评估总症状评分(MPN-SAF TSS)与遗传负担和血栓形成在慢性骨髓增殖性肿瘤中的关系。
Turk J Haematol. 2024 Aug 28;41(3):175-181. doi: 10.4274/tjh.galenos.2024.2024.0011. Epub 2024 May 27.
8
EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS.使用优化的自我评估MPN-SAF TSS评估放射性相关和自发性骨髓增殖性肿瘤患者的负担性症状
Probl Radiac Med Radiobiol. 2018 Dec;23:510-516. doi: 10.33145/2304-8336-2018-23-510-516.
9
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.骨髓增殖性肿瘤(MPN)的进展:诊断与治疗视角。
Cells. 2021 Dec 16;10(12):3551. doi: 10.3390/cells10123551.
10
[Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].108例骨髓增殖性肿瘤患者基因突变与临床特征分析
Zhonghua Xue Ye Xue Za Zhi. 2020 Jul 14;41(7):576-582. doi: 10.3760/cma.j.issn.0253-2727.2020.07.008.

引用本文的文献

1
Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.真性红细胞增多症、特发性血小板增多症和原发性骨髓纤维化的分析研究系统评价及 JAK2、CALR 和 MPL 突变频率的荟萃分析:2000-2018 年。
BMC Cancer. 2019 Jun 17;19(1):590. doi: 10.1186/s12885-019-5764-4.

本文引用的文献

1
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.芦可替尼与标准疗法治疗真性红细胞增多症的对比
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
2
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.芦可替尼:一种用于治疗骨髓纤维化的口服 Janus 激酶 1 和 Janus 激酶 2 抑制剂。
Postgrad Med. 2013 Jan;125(1):128-35. doi: 10.3810/pgm.2013.01.2628.
3
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
骨髓增殖性肿瘤 (MPN) 症状评估表总症状评分:在 MPN 患者中前瞻性国际评估简化症状负担评分系统。
J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15.
4
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
5
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.骨髓增殖性肿瘤症状评估表(MPN-SAF):402 例患者的国际前瞻性验证和可靠性研究。
Blood. 2011 Jul 14;118(2):401-8. doi: 10.1182/blood-2011-01-328955. Epub 2011 May 2.
6
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.INCB018424,一种 JAK1 和 JAK2 抑制剂,在骨髓纤维化中的安全性和疗效。
N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.
7
A gain-of-function mutation of JAK2 in myeloproliferative disorders.骨髓增殖性疾病中JAK2的功能获得性突变。
N Engl J Med. 2005 Apr 28;352(17):1779-90. doi: 10.1056/NEJMoa051113.
8
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.一种导致持续性信号传导的独特克隆性JAK2突变会引发真性红细胞增多症。
Nature. 2005 Apr 28;434(7037):1144-8. doi: 10.1038/nature03546.
9
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.人类骨髓增殖性疾病中酪氨酸激酶JAK2的获得性突变。
Lancet. 2005;365(9464):1054-61. doi: 10.1016/S0140-6736(05)71142-9.
10
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症患者的预期寿命及生存预后因素。
Am J Med. 2004 Nov 15;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032.